Weight loss, GLP-1s and Sarcopenia: A Podcast with John Batsis, Shen Dewar, Aruna Josyula

GLP-1 receptor agonists (the "Ozempics of the world") have been a truly revolutionary pharmacological advance in modern medicine. In randomized controlled trials (RCTs), these agents have been shown to do much more than just reduce weight, including significantly reducing cardiovascular events, lowering all-cause mortality in patients with type 2 diabetes, and even slowing the progression of chronic kidney disease.

But as we see their use rapidly expand among older adults, we have to ask: at what cost?

In geriatrics, weight loss is rarely simple. In older bodies, GLP1s carry increased risks, including accelerated muscle loss, functional decline, and possibly decreased bone density. So are we just trading weight loss for frailty?

To help us untangle this complex web, we sit down with three expert geriatricians in obesity: Dr. John Batsis, Dr. Shen Dewar, and Dr. Aruna Josyula.

What We Discuss in This Episode:

How age-related changes alter the distribution of fat and muscle, even when body weight stays exactly the same.

What are sarcopenia (muscle loss) and sarcopenic obesity, and why are they so dangerous for independence?

A discussion on what happens to fat, muscle, and bone during standard weight loss versus weight loss accelerated by GLP-1s.

Whether GLP-1-induced muscle loss a direct biological side effect from suppressed muscle protein synthesis, or is it simply the indirect result of a massive caloric deficit and dropping protein intake?

A broad, geriatric-focused approach to weight, including a vital review of common medications that might actually be causing weight gain in the first place.

Practical, actionable strategies to protect muscle mass and function when prescribing GLP1s

A discussion of red flags in older adults, where we should have major hesitation before ever writing a prescription for a GLP-1